GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » Price-to-Owner-Earnings

Takara Bio (TSE:4974) Price-to-Owner-Earnings : 6.92 (As of May. 22, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Takara Bio Price-to-Owner-Earnings?

As of today (2024-05-22), Takara Bio's share price is 円1092.00. Takara Bio's Owner Earnings per Share (TTM) ended in Dec. 2023 was 円157.74. It's Price-to-Owner-Earnings for today is 6.92.


The historical rank and industry rank for Takara Bio's Price-to-Owner-Earnings or its related term are showing as below:

TSE:4974' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.62   Med: 119.63   Max: 3340.91
Current: 6.88

During the past 13 years, the highest Price-to-Owner-Earnings of Takara Bio was 3340.91. The lowest was 5.62. And the median was 119.63.


TSE:4974's Price-to-Owner-Earnings is ranked better than
90.74% of 162 companies
in the Biotechnology industry
Industry Median: 33.52 vs TSE:4974: 6.88

As of today (2024-05-22), Takara Bio's share price is 円1092.00. Takara Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円13.04. Therefore, Takara Bio's PE Ratio for today is 83.76.

As of today (2024-05-22), Takara Bio's share price is 円1092.00. Takara Bio's EPS without NRI for the trailing twelve months (TTM) ended in was 円15.50. Therefore, Takara Bio's PE Ratio without NRI for today is 70.45.

During the past 13 years, Takara Bio's highest PE Ratio without NRI was 366.38. The lowest was 10.07. And the median was 77.08.


Takara Bio Price-to-Owner-Earnings Historical Data

The historical data trend for Takara Bio's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio Price-to-Owner-Earnings Chart

Takara Bio Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 115.23 106.97 43.85 - 6.00

Takara Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 207.12 6.00 7.20 6.95 7.94

Competitive Comparison of Takara Bio's Price-to-Owner-Earnings

For the Biotechnology subindustry, Takara Bio's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takara Bio's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Takara Bio's Price-to-Owner-Earnings falls into.



Takara Bio Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Takara Bio's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1092.00/157.74
=6.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takara Bio  (TSE:4974) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Takara Bio Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Takara Bio's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Takara Bio (TSE:4974) Business Description

Traded in Other Exchanges
Address
Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio (TSE:4974) Headlines

No Headlines